Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients

John Hammerstad, William Woodward, John Nutt, S. T. Gancher, G. A. Block, G. Cyhan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.

Original languageEnglish (US)
Pages (from-to)429-434
Number of pages6
JournalClinical Neuropharmacology
Volume17
Issue number5
StatePublished - 1994

Fingerprint

Pharmacokinetics
Levodopa
Biological Availability
Half-Life
levodopa drug combination carbidopa
Therapeutics

Keywords

  • Controlled release levodopa/carbidopa (Sinemet CR) 25/100
  • Levodopa
  • Parkinson's disease
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{d86fd4b077d54086a18155fa3b2f8c84,
title = "Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients",
abstract = "The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.",
keywords = "Controlled release levodopa/carbidopa (Sinemet CR) 25/100, Levodopa, Parkinson's disease, Pharmacokinetics",
author = "John Hammerstad and William Woodward and John Nutt and Gancher, {S. T.} and Block, {G. A.} and G. Cyhan",
year = "1994",
language = "English (US)",
volume = "17",
pages = "429--434",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100)

T2 - Pharmacokinetics and clinical efficacy in untreated parkinsonian patients

AU - Hammerstad, John

AU - Woodward, William

AU - Nutt, John

AU - Gancher, S. T.

AU - Block, G. A.

AU - Cyhan, G.

PY - 1994

Y1 - 1994

N2 - The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.

AB - The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.

KW - Controlled release levodopa/carbidopa (Sinemet CR) 25/100

KW - Levodopa

KW - Parkinson's disease

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0028085949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028085949&partnerID=8YFLogxK

M3 - Article

C2 - 9316692

AN - SCOPUS:0028085949

VL - 17

SP - 429

EP - 434

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -